|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cairns P: Renal cell carcinoma. Cancer
Biomark. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Decastro GJ and McKiernan JM:
Epidemiology, clinical staging, and presentation of renal cell
carcinoma. Urol Clin North Am. 35(581–592): vi2008.
|
|
6
|
Ljungberg B, Cowan NC, Hanbury DC, Hora M,
Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC:
European Association of Urology Guideline Group: EAU guidelines on
renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park I, Lee JL, Ahn JH, Lee DH, Lee KH,
Jeong IG, Song C, Hong B, Hong JH and Ahn H: Active surveillance
for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin
Oncol. 140:1421–1428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirata H, Hinoda Y, Ueno K, Nakajima K,
Ishii N and Dahiya R: MicroRNA-1826 directly targets beta-catenin
(CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.
Carcinogenesis. 33:501–508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Planell-Saguer M and Rodicio MC:
Analytical aspects of microRNA in diagnostics: A review. Anal Chim
Acta. 699:134–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ha TY: MicroRNAs in human diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang Y, Wan W, Wang L, Ji S and Zhang J:
microRNA-451 inhibited cell proliferation, migration and invasion
through regulation of MIF in renal cell carcinoma. Int J Clin Exp
Pathol. 8:15611–15621. 2015.PubMed/NCBI
|
|
15
|
Shi Q, Xu X, Liu Q, Luo F, Shi J and He X:
MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K
in renal cell carcinoma. Oncol Lett. 11:1474–1480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao Y, Ma X, Yao Y, Li H, Fan Y, Zhang Y,
Zhao C, Wang L, Ma M, Lei Z and Zhang X: miR-155 regulates the
proliferation and invasion of clear cell renal cell carcinoma cells
by targeting E2F2. Oncotarget. 7:20324–20337. 2016.PubMed/NCBI
|
|
17
|
Li Y, Chen D, Jin LU, Liu J, Li Y, Su Z,
Qi Z, Shi M, Jiang Z, Yang S, et al: Oncogenic microRNA-142-3p is
associated with cellular migration, proliferation and apoptosis in
renal cell carcinoma. Oncol Lett. 11:1235–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu
Z, Hu G and Yang Q: MicroRNA-30a suppresses breast tumor growth and
metastasis by targeting metadherin. Oncogene. 33:3119–3128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang R, Liang L, Luo D, Feng Z, Huang Q,
He R, Gan T, Yang L and Chen G: Downregulation of MiR-30a is
associated with poor prognosis in lung cancer. Med Sci Monit.
21:2514–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang C, Ma X, Du J, Yao Z, Shi T, Ai Q,
Chen X, Zhang Z, Zhang X and Yao X: MicroRNA-30a as a prognostic
factor in urothelial carcinoma of bladder inhibits cellular
malignancy by antagonising Notch1. BJU Int. 118:578–589. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li WF, Dai H, Ou Q, Zuo GQ and Liu CA:
Overexpression of microRNA-30a-5p inhibits liver cancer cell
proliferation and induces apoptosis by targeting MTDH/PTEN/AKT
pathway. Tumour Biol. 37:5885–5895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Z, Chen L, Zhang X, Xu X, Xing H,
Zhang Y, Li W, Yu H, Zeng J and Jia J: RUNX3 regulates vimentin
expression via miR-30a during epithelial-mesenchymal transition in
gastric cancer cells. J Cell Mol Med. 18:610–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong M, Bian Z and Wu Z: miR-30a
suppresses cell migration and invasion through downregulation of
PIK3CD in colorectal carcinoma. Cell Physiol Biochem. 31:209–218.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao
J, Wang Y, Yang S and Pu P: Analysis of hsa-miR-30a-5p expression
in human gliomas. Pathol Oncol Res. 19:405–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng CW, Wang HW, Chang CW, Chu HW, Chen
CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a
inhibits cell migration and invasion by downregulating vimentin
expression and is a potential prognostic marker in breast cancer.
Breast Cancer Res Treat. 134:1081–1093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wen XP, Ma HL, Zhao LY, Zhang W and Dang
CX: MiR-30a suppresses non-small cell lung cancer progression
through AKT signaling pathway by targeting IGF1R. Cell Mol Biol
(Noisy-le-grand). 61:78–85. 2015.PubMed/NCBI
|
|
28
|
Yuan Y, Zheng S, Li Q, Xiang X, Gao T, Ran
P, Sun L, Huang Q, Xie F, Du J and Xiao C: Overexpression of
miR-30a in lung adenocarcinoma A549 cell line inhibits migration
and invasion via targeting EYA2. Acta Biochim Biophys Sin
(Shanghai). 48:220–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Dai X, Chen Y, Sun C, Zhu Q, Zhao
H, Liu G, Huang Q and Lan Q: MiR-30a-5p is induced by Wnt/β-catenin
pathway and promotes glioma cell invasion by repressing NCAM.
Biochem Biophys Res Commun. 465:374–380. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jia Z, Wang K, Wang G, Zhang A and Pu P:
MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth
by targeting SEPT7. PLoS One. 8:e550082013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang HY, Li YY, Fu S, Wang XP, Huang MY,
Zhang X, Shao Q, Deng L, Zeng MS, Zeng YX and Shao JY: MicroRNA-30a
promotes invasiveness and metastasis in vitro and in vivo through
epithelial-mesenchymal transition and results in poor survival of
nasopharyngeal carcinoma patients. Exp Biol Med (Maywood).
239:891–898. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiong J, Wei B, Ye Q and Liu W:
MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation
and migration. Biochem Biophys Res Commun. 18–Mar;2016.(Epub ahead
of print). View Article : Google Scholar
|
|
34
|
Chang CW, Yu JC, Hsieh YH, Yao CC, Chao
JI, Chen PM, Hsieh HY, Hsiung CN, Chu HW, Shen CY and Cheng CW:
MicroRNA-30a increases tight junction protein expression to
suppress the epithelial-mesenchymal transition and metastasis by
targeting Slug in breast cancer. Oncotarget. 7:16462–16478.
2016.PubMed/NCBI
|
|
35
|
Sestito R, Cianfrocca R, Rosanò L, Tocci
P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A,
Blandino G and Bagnato A: miR-30a inhibits endothelin A receptor
and chemoresistance in ovarian carcinoma. Oncotarget. 7:4009–4023.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang D, Zheng X, Shan W and Shan Y: The
overexpression of miR-30a affects cell proliferation of
chondrosarcoma via targeting Runx2. Tumour Biol. 37:5933–5940.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guaiquil V, Swendeman S, Yoshida T,
Chavala S, Campochiaro PA and Blobel CP: ADAM9 is involved in
pathological retinal neovascularization. Mol Cell Biol.
29:2694–2703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duffy MJ, McKiernan E, O'Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fritzsche FR, Wassermann K, Jung M, Tölle
A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and
Kristiansen G: ADAM9 is highly expressed in renal cell cancer and
is associated with tumour progression. BMC Cancer. 8:1792008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang S, Wang X, Guo Q, Wang G, Han X, Li
X, Shi ZW and He W: MicroRNA-126 overexpression inhibits
proliferation and invasion in osteosarcoma cells. Technol Cancer
Res Treat. 15:NP49–NP59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma
CY, Hua SC, Yang M and Yuan Q: microRNA-1274a, a modulator of
sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9)
down-regulation in hepatocellular carcinoma. FEBS Lett.
585:1828–1834. 2011. View Article : Google Scholar : PubMed/NCBI
|
